Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.53 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 4/20 | 0.35 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28421702 | 0.89 | ZDHHC20 (0.59) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL10080729 | 0.87 | ZDHHC20 (0.62) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL2611992 | 0.85 | ZDHHC20 (0.66) | ZDHHC20ZDHHC2TSHRFAAHSMN1; SMN2 | |
| SCHEMBL24760765 | 0.82 | ZDHHC20 (0.55) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL12310195 | 0.82 | ZDHHC20 (0.50) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL17047583 | 0.80 | TSHR (0.62) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL15005 | 0.80 | — | — | |
| SCHEMBL10821153 | 0.79 | TSHR (0.50) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL8376831 | 0.79 | TSHR (0.50) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL641627 | 0.79 | ZDHHC20 (0.62) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158021-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystalline polymer, and optical anisotropic article | ZEON CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | ZEON CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100258764-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE | LEO1, ZYX, CCNT1 | ZDHHC20 1156/4885ZDHHC2 565/4885TSHR 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.